Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pharmalactis Breathe
- Development stage
- Preclinical
- Lead developer
- Zinereo Pharma
- Modality
- Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Pharmalactis Breathe is a probiotic food supplement developed by Zinereo Pharma, a subsidiary of the Zendal group. It is specifically formulated to support respiratory health and reduce the incidence of upper respiratory infections (URIs). As a live biotherapeutic product, it functions by modulating the host's immune system and maintaining the homeostasis of the respiratory microbiota. The product is part of Zinereo's Pharmalactis line, which focuses on leveraging specific probiotic strains for targeted health benefits, positioning it as a nutraceutical intervention for respiratory wellness.
- Brand names
- Pharmalactis Breathe
Beyond the preview
Go deeper on Pharmalactis Breathe.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pharmalactis Breathe.